Description
RBN-2397 is a potent, accross species and orally active NAD+ competitive inhibitor of PARP7 (IC50<3 nM). RBN-2397 selectively binds to PARP7 (Kd=0.001 µM) and restores IFN signaling. RBN-2397 has the potential for the study of advanced or metastatic solid tumors